Literature DB >> 14634715

Unconditional hyperactivity and transient reinforcing effects of NMDA administration into the ventral tegmental area in rats.

Satoshi Ikemoto1.   

Abstract

RATIONALE: The dopaminergic projection from the ventral tegmental area (VTA) to the nucleus accumbens plays an important role in positive reinforcement and locomotion. Intra-VTA administration of many drugs capable of activating these neurons has been shown to be reinforcing and induce locomotion. Administration of the excitatory amino acid NMDA (N-methyl-D-aspartate) into the VTA may likewise be positively reinforcing, because it stimulates the meso-accumbens dopamine system and locomotion. OBJECTIVES AND METHODS: Locomotor-rearing experiments were conducted to pinpoint the range of NMDA concentrations that induce significant locomotion and rearing, and to determine whether co-administration of the glycine binding site agonist d-serine would enhance the effects of NMDA administration into the VTA. Reinforcing effects of NMDA were assessed by intracranial self-administration procedures: a lever-press delivered a 75-nl infusion containing NMDA (0.1, 0.3 or 1.0 mM) plus serine into the VTA or an adjacent region, the supramammillary nucleus.
RESULTS: Co-administration of serine slightly enhanced rearing induced by NMDA administration. Administration of NMDA at concentrations of 0.3 or 1.0 mM (500 nl) induced vigorous locomotion and rearing. NMDA (0.3 mM) was self-administered into the VTA slightly more than vehicle in the first or second sessions, yet this small reinforcing effect became irregular in subsequent sessions. The rats did not learn to self-administer NMDA into the supramammillary nucleus.
CONCLUSIONS: Ventral tegmental NMDA injections, in the concentration range that induced marked unconditional hyperactivity, supported only marginal and transient self-administration.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14634715     DOI: 10.1007/s00213-003-1651-3

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  52 in total

1.  Regional heterogeneity for the intracranial self-administration of ethanol within the ventral tegmental area of female Wistar rats.

Authors:  Z A Rodd-Henricks; D L McKinzie; R S Crile; J M Murphy; W J McBride
Journal:  Psychopharmacology (Berl)       Date:  2000-04       Impact factor: 4.530

2.  Rewarding injections of the cholinergic agonist carbachol into the ventral tegmental area induce locomotion and c-Fos expression in the retrosplenial area and supramammillary nucleus.

Authors:  Satoshi Ikemoto; Brian M Witkin; Marisela Morales
Journal:  Brain Res       Date:  2003-04-18       Impact factor: 3.252

3.  Self-administration of the GABAA antagonist bicuculline into the ventral tegmental area in mice: dependence on D2 dopaminergic mechanisms.

Authors:  V David; T P Durkin; P Cazala
Journal:  Psychopharmacology (Berl)       Date:  1997-03       Impact factor: 4.530

Review 4.  The glycine site of the NMDA receptor--five years on.

Authors:  J A Kemp; P D Leeson
Journal:  Trends Pharmacol Sci       Date:  1993-01       Impact factor: 14.819

5.  Regulation of the mesocorticolimbic dopamine system by glutamic acid receptor subtypes.

Authors:  P W Kalivas; P Duffy; J Barrow
Journal:  J Pharmacol Exp Ther       Date:  1989-10       Impact factor: 4.030

6.  Rewarding and psychomotor stimulant effects of endomorphin-1: anteroposterior differences within the ventral tegmental area and lack of effect in nucleus accumbens.

Authors:  Abraham Zangen; Satoshi Ikemoto; James E Zadina; Roy A Wise
Journal:  J Neurosci       Date:  2002-08-15       Impact factor: 6.167

7.  Critical role for ventral tegmental glutamate in preference for a cocaine-conditioned environment.

Authors:  Glenda C Harris; Gary Aston-Jones
Journal:  Neuropsychopharmacology       Date:  2003-01       Impact factor: 7.853

8.  Tonic activation of NMDA receptors causes spontaneous burst discharge of rat midbrain dopamine neurons in vivo.

Authors:  K Chergui; P J Charléty; H Akaoka; C F Saunier; J L Brunet; M Buda; T H Svensson; G Chouvet
Journal:  Eur J Neurosci       Date:  1993-02-01       Impact factor: 3.386

9.  Suppression of exploratory locomotor activity and increase in dopamine turnover following the local application of cis-flupenthixol into limbic projection areas of the rat striatum.

Authors:  S Ahlenius; V Hillegaart; G Thorell; O Magnusson; C J Fowler
Journal:  Brain Res       Date:  1987-01-27       Impact factor: 3.252

10.  L-glutamate excitation of A10 dopamine neurons is preferentially mediated by activation of NMDA receptors: extra- and intracellular electrophysiological studies in brain slices.

Authors:  T Wang; E D French
Journal:  Brain Res       Date:  1993-11-12       Impact factor: 3.252

View more
  5 in total

Review 1.  Behavioral functions of the mesolimbic dopaminergic system: an affective neuroethological perspective.

Authors:  Antonio Alcaro; Robert Huber; Jaak Panksepp
Journal:  Brain Res Rev       Date:  2007-08-21

Review 2.  Opioid-induced rewards, locomotion, and dopamine activation: A proposed model for control by mesopontine and rostromedial tegmental neurons.

Authors:  Stephan Steidl; David I Wasserman; Charles D Blaha; John S Yeomans
Journal:  Neurosci Biobehav Rev       Date:  2017-09-23       Impact factor: 8.989

3.  Divergent activation of ventromedial and ventrolateral dopamine systems in animal models of amphetamine sensitization and schizophrenia.

Authors:  Daniel J Lodge; Anthony A Grace
Journal:  Int J Neuropsychopharmacol       Date:  2011-02-18       Impact factor: 5.176

Review 4.  Dopamine reward circuitry: two projection systems from the ventral midbrain to the nucleus accumbens-olfactory tubercle complex.

Authors:  Satoshi Ikemoto
Journal:  Brain Res Rev       Date:  2007-05-17

5.  Synaptic overflow of dopamine in the nucleus accumbens arises from neuronal activity in the ventral tegmental area.

Authors:  Leslie A Sombers; Manna Beyene; Regina M Carelli; R Mark Wightman
Journal:  J Neurosci       Date:  2009-02-11       Impact factor: 6.167

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.